Tag: orsiro
HOST-IDEA sub-analysis uncovers differences in ultrathin stent platforms
Results of a stent-level analysis from the HOST-IDEA study, which compared two ultrathin strut d...
CRT 2022: Final BIOFLOW-V results “affirm durability” of Orsiro out to five years
Final five-year results from the BIOFLOW-V trial, presented during a late-breaking trial session...
CRT 2021: Biodegradable polymer sirolimus-eluting stent shows ‘promising’ results in STEMI patients
Thomas Pilgrim (Bern, Switerland) details two-year results from the BIOSTEMI randomised trial, whi...
Resolute Onyx matches Orsiro at two years in all-comers’ patients
Two-year data from the BIONYX trial show that all-comer patients who underwent percutaneous coro...
Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro
According to recently presented TICO trial data, a press release reports, patients with acute co...
CRT 2020: Biotronik reports three-year results for Orsiro DES from BIOFLOW-V trial
Biotronik has announced three-year data from the BIOFLOW-V trial, which were presented at the Ca...
ESC 2019: Ultrathin strut Orsiro better than thin strut Xience for STEMI patients
One-year data from the BIOSTEMI study, simultaneously published in The Lancet and presented at t...
EuroPCR 2019: Ultrathin stent demonstrates benefits in small vessels
Late-breaking trial data presented at EuroPCR 2019 (20–24 May, Paris, France) on three year outc...
CRT 2019: Three-year data shows trend towards lower target vessel failure with Orsiro vs. Resolute Integrity and Synergy
Three-year outcome data from the BIO-RESORT randomised controlled trial, which were presented at...
FDA approves Orsiro for use in the USA
The US FDA have approved Biotronik’s drug-eluting stent Orsiro. A press release states...
Orsiro may be the new benchmark for comparison in drug-eluting stent trials
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego,...
TCT 2018: Orsiro continues to have lower rates of target lesion failure than Xience
Two-year data from the BIOFLOW-V randomised trial—which compared a sirolimus stent with a biodeg...
TCT 2018: Lower rate of stent thrombosis with Resolute Onyx vs. Orsiro
Data presented yesterday at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21...
ESC 2018: Higher all-cause mortality with Orsiro at five years than with Xience
According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biod...
EuroPCR 2018: One- to two-year landmark analysis shows significantly lower target lesion failure with Orsiro vs. Resolute Integrity
Two-year outcome data from the BIO-RESORT randomised controlled trial, which were presented in a...
CIT 2018: BIOFLOW-VI confirms non-inferiority of Orsiro to Xience
Nine and 12-month data for Orsiro—presented by Yang Yue Jin (Fu-Wai Hospital, National Center of...
Enrolment complete in BIOSTEMI study
Biotronik has announced that patient enrolment for the BIOSTEMI study has been completed. A pres...
Japanese Ministry of Health approve Biotronik’s Orsiro drug-eluting stent
According to a Biotronik press release, the Japanese Ministry of Health has approved the company...
ESC 2017: Significantly lower event rates with Orsiro than with Xience
Results from the BIOFLOW V study indicate that patients who undergo percutaneous coron...
BIOFLOW-IV confirms non-inferiority of Biotronik’s Orsiro in Japan
The 12-month results of Biotronik’s BIOFLOW-IV multicentre clinical study have been presented at...
TCT 2016: All comers study finds no differences between Orsiro, Synergy and Resolute Integrity
BIO-RESORT, presented at TCT today during a late-breaking trial session, has found no significant di...
Risk of device thrombosis may be significantly higher with Absorb than with Xience, Promus or Orsiro
A network meta-analysis, published in JACC: Cardiovascular Interventions, indicates that three c...